Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2019-06-27 Regulatory Filings
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 279.2KB
Regulatory Filings Classification · 95% confidence The document is a market announcement regarding a trading halt requested by Lifespot Health Ltd pending the release of an announcement related to a material product development and distribution Heads of Agreement. It is dated 28 June 2019 and references ASX Listing Rule 17.1. The document does not contain any financial data, report content, or detailed disclosures but is a short notice about the trading halt itself. It is an announcement about a forthcoming announcement, not a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-06-27 English
Appendix 3B 14 pages 424.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, specifically unlisted options, including terms, number of securities, issue price, purpose, and compliance with ASX rules. It references ASX listing rules (e.g., Rule 7.1A) and includes a calculation of placement capacity under these rules. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new issue of securities and application for quotation of additional securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement.
2019-06-04 English
Change of Directors' Interest Notices 7 pages 298.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including acquisition of unlisted options and shares. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements, earnings data, or management discussion, but rather reports insider trades by directors. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is over 10,000 characters and contains detailed transaction data, confirming it is the report itself, not just an announcement. Therefore, the correct classification is DIRS.
2019-06-04 English
Results of Meeting 2 pages 294.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 24 May 2019 reporting the results of an Annual General Meeting (AGM) of Lifespot Health Limited. It details the resolutions passed by shareholders, including votes for and against various items such as the Remuneration Report, re-election of directors, and approval of share issues. The content is focused on the official voting results from the AGM, not the full AGM materials or presentations. The document length is short (2411 characters), and it explicitly states it is providing results of the meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-05-23 English
Quarter 1 Update 3 pages 302.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 26 April 2019 providing a quarterly update on business development progress and financial highlights for the March 2019 quarter. It includes operational highlights, cash reserves, revenues, recruitment updates, product launches, and market outlook. The document references the Appendix 4C for the quarter, which is a standard quarterly cash flow report for ASX-listed companies. The content focuses on business development progress and operational updates rather than detailed financial statements or comprehensive financial analysis. The length is about 5235 characters, which is relatively short and consistent with an announcement rather than a full interim or quarterly report. There are no detailed financial statements or substantive financial data presented, only summary operational and financial highlights. Therefore, this document fits best as a Capital/Financing Update (CAP) because it provides an update on the company's operational and financial status for the quarter, including cash reserves and expenditure, but does not contain full financial statements or detailed analysis required for an Interim/Quarterly Report (IR).
2019-04-25 English
Appendix 4C - quarterly 5 pages 212.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed quarterly financial data including consolidated statements of cash flows, cash equivalents, payments to directors, financing facilities, estimated cash outflows, and acquisitions/disposals. It covers the quarter ended 31 March 2019. The content is substantive financial data for a period shorter than a full fiscal year, consistent with an interim or quarterly report. The document length is 8178 characters, which is sufficient to contain actual financial data rather than just an announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-04-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.